Let's Declare Our Independence From Foreign Drug Supply Chains

While Americans prepare to gather for Independence Day on July 4, there is a silent crisis that threatens the quality of life for every American.

Since the start of COVID-19, increasing attention has been paid to shortages across our supply chains. From baby formula to auto parts, it seems like everything is out of stock. But unlike many products, patients can’t afford to wait around for drugs and medical supplies to arrive.

Congress has a rare opportunity to work in a bipartisan and bicameral fashion to improve medical supply chain security, reduce the United States’s dependence on China for pharmaceuticals, and foster U.S.-made manufacturing of drugs, devices, and personal protective equipment.

“We need to incentivize production here at home,” said Tony Paquin, Chief Executive Officer at iRemedy Healthcare, Inc. “The only way to do that is to have U.S. suppliers to ensure there’s a network to get critical products to patients.”

Paquin’s comments, like many across the industry, have resonated in the halls of Congress, where legislation is coming forward to incentivize production. The Manufacturing API, Drugs, and Excipients (MADE) in America Act, introduced by Republican Sen. Tim Scott of South Carolina and Democratic Sen. Jacky Rosen of Nevada, would improve the

View Source